Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Field Operations Would Endure Reductions Under Budget

Executive Summary

President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.

Advertisement

Related Content

FDA Smart Growth Strategy: More Room At White Oak, Less In Budget
FDA's Smart Growth Strategy: More Room At White Oak, Less In Budget
Energy And Commerce Members Want FDA Overseas Operations Update
FDA Posts Investigator In Singapore, But Trims Foreign Office List
Priority Review Vouchers Could Be Used Frequently Next Year
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
FDA Could Release GMP Data To Prod Manufacturing Improvements
FDA’s Budget Proposal: It’s The User Fees’ Agency Now
FDA User Fee Bill Up For Final Senate Action After House Passage
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS056638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel